• Je něco špatně v tomto záznamu ?

Reduced murine double minute 2 and 4 protein, but not messenger RNA, expression is associated with more severe disease in myelodysplastic syndromes and acute myeloblastic leukaemia

N. Salomao, N. Maslah, A. Giulianelli, L. Drevon, L. Aguinaga, X. Gu, B. Cassinat, S. Giraudier, P. Fenaux, R. Fahraeus

. 2023 ; 201 (2) : 234-248. [pub] 20221222

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23010585

The human homologues of murine double minute 2 (MDM2) and 4 (MDM4) negatively regulate p53 tumour suppressor activity and are reported to be frequently overexpressed in human malignancies, prompting clinical trials with drugs that prevent interactions between MDM2/MDM4 and p53. Bone marrow samples from 111 patients with acute myeloblastic leukaemia, myelodysplastic syndrome or chronic myelomonocytic leukaemia were examined for protein (fluorescence-activated cell sorting) and messenger RNA (mRNA) expression (quantitative polymerase chain reaction) of MDM2, MDM4 and tumour protein p53 (TP53). Low protein expression of MDM2 and MDM4 was observed in immature cells from patients with excess of marrow blasts (>5%) compared with CD34+ /CD45low cells from healthy donors and patients without excess of marrow blasts (<5%). The mRNA levels were indistinguishable in all samples examined regardless of disease status or blast levels. Low MDM2 and MDM4 protein expression were correlated with poor survival. These data show a poor correlation between mRNA and protein expression levels, suggesting that quantitative flow cytometry analysis of protein expression levels should be used to predict and validate the efficacy of MDM2 and MDM4 inhibitors. These findings show that advanced disease is associated with reduced MDM2 and MDM4 protein expression and indicate that the utility of MDM2 and MDM4 inhibitors may have to be reconsidered in the treatment of advanced myeloid malignancies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010585
003      
CZ-PrNML
005      
20230801132521.0
007      
ta
008      
230718s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjh.18608 $2 doi
035    __
$a (PubMed)36546586
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Salomao, Norman $u Inserm UMRS1131, Institut de Recherche Saint-Louis, Institut de Génétique Moléculaire, Université de Paris-Cité, Hôpital St. Louis, Paris, France $1 https://orcid.org/0000000237001088
245    10
$a Reduced murine double minute 2 and 4 protein, but not messenger RNA, expression is associated with more severe disease in myelodysplastic syndromes and acute myeloblastic leukaemia / $c N. Salomao, N. Maslah, A. Giulianelli, L. Drevon, L. Aguinaga, X. Gu, B. Cassinat, S. Giraudier, P. Fenaux, R. Fahraeus
520    9_
$a The human homologues of murine double minute 2 (MDM2) and 4 (MDM4) negatively regulate p53 tumour suppressor activity and are reported to be frequently overexpressed in human malignancies, prompting clinical trials with drugs that prevent interactions between MDM2/MDM4 and p53. Bone marrow samples from 111 patients with acute myeloblastic leukaemia, myelodysplastic syndrome or chronic myelomonocytic leukaemia were examined for protein (fluorescence-activated cell sorting) and messenger RNA (mRNA) expression (quantitative polymerase chain reaction) of MDM2, MDM4 and tumour protein p53 (TP53). Low protein expression of MDM2 and MDM4 was observed in immature cells from patients with excess of marrow blasts (>5%) compared with CD34+ /CD45low cells from healthy donors and patients without excess of marrow blasts (<5%). The mRNA levels were indistinguishable in all samples examined regardless of disease status or blast levels. Low MDM2 and MDM4 protein expression were correlated with poor survival. These data show a poor correlation between mRNA and protein expression levels, suggesting that quantitative flow cytometry analysis of protein expression levels should be used to predict and validate the efficacy of MDM2 and MDM4 inhibitors. These findings show that advanced disease is associated with reduced MDM2 and MDM4 protein expression and indicate that the utility of MDM2 and MDM4 inhibitors may have to be reconsidered in the treatment of advanced myeloid malignancies.
650    _2
$a lidé $7 D006801
650    _2
$a myši $7 D051379
650    _2
$a zvířata $7 D000818
650    _2
$a protoonkogenní proteiny c-mdm2 $x genetika $x metabolismus $7 D051736
650    _2
$a protoonkogenní proteiny $x genetika $7 D011518
650    _2
$a nádorový supresorový protein p53 $x genetika $7 D016159
650    _2
$a messenger RNA $x genetika $x metabolismus $7 D012333
650    12
$a akutní myeloidní leukemie $x genetika $7 D015470
650    12
$a myelodysplastické syndromy $x genetika $7 D009190
650    _2
$a proteiny buněčného cyklu $x genetika $x metabolismus $7 D018797
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Maslah, Nabih $u Inserm UMRS1131, Institut de Recherche Saint-Louis, Institut de Génétique Moléculaire, Université de Paris-Cité, Hôpital St. Louis, Paris, France
700    1_
$a Giulianelli, Anouk $u Service d'Hématologie Senior-Hôpital Saint-Louis-Assistance Publique Hôpitaux de Paris, and Paris Cité university, Paris, France
700    1_
$a Drevon, Louis $u Inserm UMRS1131, Institut de Recherche Saint-Louis, Institut de Génétique Moléculaire, Université de Paris-Cité, Hôpital St. Louis, Paris, France $u Service d'Hématologie Senior-Hôpital Saint-Louis-Assistance Publique Hôpitaux de Paris, and Paris Cité university, Paris, France
700    1_
$a Aguinaga, Lorea $u Inserm UMRS1131, Institut de Recherche Saint-Louis, Institut de Génétique Moléculaire, Université de Paris-Cité, Hôpital St. Louis, Paris, France $u Service d'Hématologie Senior-Hôpital Saint-Louis-Assistance Publique Hôpitaux de Paris, and Paris Cité university, Paris, France
700    1_
$a Gu, Xiaolian $u Department of Medical Biosciences, Building 6M, Umeå University, Umeå, Sweden
700    1_
$a Cassinat, Bruno $u Inserm UMRS1131, Institut de Recherche Saint-Louis, Institut de Génétique Moléculaire, Université de Paris-Cité, Hôpital St. Louis, Paris, France $u Service d'Hématologie Senior-Hôpital Saint-Louis-Assistance Publique Hôpitaux de Paris, and Paris Cité university, Paris, France
700    1_
$a Giraudier, Stephane $u Inserm UMRS1131, Institut de Recherche Saint-Louis, Institut de Génétique Moléculaire, Université de Paris-Cité, Hôpital St. Louis, Paris, France $u Service d'Hématologie Senior-Hôpital Saint-Louis-Assistance Publique Hôpitaux de Paris, and Paris Cité university, Paris, France
700    1_
$a Fenaux, Pierre $u Service d'Hématologie Senior-Hôpital Saint-Louis-Assistance Publique Hôpitaux de Paris, and Paris Cité university, Paris, France $1 https://orcid.org/0000000204683553
700    1_
$a Fahraeus, Robin $u Inserm UMRS1131, Institut de Recherche Saint-Louis, Institut de Génétique Moléculaire, Université de Paris-Cité, Hôpital St. Louis, Paris, France $u Department of Medical Biosciences, Building 6M, Umeå University, Umeå, Sweden $u RECAMO, Masaryk Memorial Cancer Institute, Brno, Czech Republic
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 201, č. 2 (2023), s. 234-248
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36546586 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132518 $b ABA008
999    __
$a ok $b bmc $g 1963175 $s 1196850
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 201 $c 2 $d 234-248 $e 20221222 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
LZP    __
$a Pubmed-20230718

Najít záznam

Citační ukazatele

Možnosti archivace